Johnson Investment Counsel Inc. Grows Holdings in Danaher Corporation $DHR

Johnson Investment Counsel Inc. boosted its holdings in shares of Danaher Corporation (NYSE:DHRFree Report) by 2.9% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 664,705 shares of the conglomerate’s stock after purchasing an additional 18,744 shares during the period. Danaher makes up 1.1% of Johnson Investment Counsel Inc.’s investment portfolio, making the stock its 21st largest holding. Johnson Investment Counsel Inc. owned about 0.09% of Danaher worth $131,784,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Sivia Capital Partners LLC increased its stake in Danaher by 6.3% in the 2nd quarter. Sivia Capital Partners LLC now owns 2,009 shares of the conglomerate’s stock valued at $397,000 after buying an additional 119 shares during the period. Concurrent Investment Advisors LLC boosted its holdings in shares of Danaher by 14.0% in the second quarter. Concurrent Investment Advisors LLC now owns 11,459 shares of the conglomerate’s stock valued at $2,264,000 after acquiring an additional 1,411 shares in the last quarter. CWM LLC increased its stake in shares of Danaher by 19.9% during the second quarter. CWM LLC now owns 36,941 shares of the conglomerate’s stock worth $7,297,000 after acquiring an additional 6,130 shares during the period. Index Fund Advisors Inc. purchased a new position in Danaher during the second quarter worth about $453,000. Finally, Allspring Global Investments Holdings LLC lifted its position in Danaher by 579.2% in the second quarter. Allspring Global Investments Holdings LLC now owns 375,863 shares of the conglomerate’s stock valued at $75,586,000 after purchasing an additional 320,521 shares during the period. 79.05% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Teri List sold 3,298 shares of the business’s stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $226.50, for a total value of $746,997.00. Following the completion of the transaction, the director owned 20,762 shares of the company’s stock, valued at $4,702,593. The trade was a 13.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Brian W. Ellis sold 21,776 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the sale, the senior vice president owned 14,553 shares in the company, valued at approximately $3,190,454.19. This trade represents a 59.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 11.20% of the company’s stock.

Danaher Stock Up 0.0%

DHR stock opened at $216.65 on Tuesday. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.87 and a quick ratio of 1.51. The company’s 50 day simple moving average is $229.47 and its 200-day simple moving average is $215.27. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $242.80. The firm has a market capitalization of $153.03 billion, a PE ratio of 42.99, a P/E/G ratio of 2.93 and a beta of 0.91.

Danaher (NYSE:DHRGet Free Report) last posted its earnings results on Wednesday, January 28th. The conglomerate reported $2.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.14 by $0.09. The firm had revenue of $6.84 billion for the quarter, compared to analyst estimates of $6.79 billion. Danaher had a return on equity of 10.81% and a net margin of 14.71%.Danaher’s revenue was up 4.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.14 EPS. Danaher has set its FY 2026 guidance at 8.350-8.500 EPS. Equities analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 30th. Investors of record on Friday, December 26th were given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date was Friday, December 26th. Danaher’s dividend payout ratio (DPR) is currently 25.40%.

Analyst Upgrades and Downgrades

DHR has been the topic of several recent analyst reports. Jefferies Financial Group boosted their target price on Danaher from $255.00 to $265.00 and gave the stock a “buy” rating in a research report on Wednesday, January 28th. Evercore reaffirmed an “outperform” rating and set a $254.00 price objective on shares of Danaher in a report on Wednesday, January 28th. Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a report on Saturday, November 22nd. KeyCorp reaffirmed an “overweight” rating on shares of Danaher in a research note on Thursday, January 29th. Finally, Wells Fargo & Company increased their price target on shares of Danaher from $230.00 to $240.00 and gave the company an “equal weight” rating in a report on Monday, December 15th. Twenty investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, Danaher has a consensus rating of “Moderate Buy” and a consensus price target of $253.86.

Read Our Latest Analysis on DHR

Danaher Company Profile

(Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.

Further Reading

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.